Including our anticipated build-out of the Ecosynthesis Innovation Lab, we continue to expect that our existing cash and cash equivalents, combined with our future expectations for product revenues, R&D revenues, and expense management, will be sufficient to fund our planned operations and cash flow grant even around the end of 2026.
Feb 28, 2024 / receipt, needs a key / Sri, CFO | earnings call 2024-02-28 | transcript 35a44d7e-3e5a-4d76-929c-4732244180af | chars 27553-27888 | segment 27
We expect that our existing cash and cash equivalents, combined with our future expectations for product revenues, R&D revenues, and expense management, will be sufficient to fund our planned operations through the end of 2024.
Aug 4, 2022 / receipt, needs a key / Ross, CFO | earnings call 2022-08-04 | transcript 8d005b30-2f6f-4b97-879d-2aac8b766292 | chars 26410-26637 | segment 26
Reduces costs and improves purity and yield
ir_statement / Sep 16, 2026 / receipt
$10B to $20B infrastructure investment required to meet anticipated annual demand of ~30K kg by ~2030
ir_statement / Sep 15, 2026 / receipt
Agilent invested $725M in facility expansion1 to produce up to 1K kg of RNAi per year
ir_statement / Sep 15, 2026 / receipt
Reduces costs and improves purity and yield
ir_statement / Sep 15, 2026 / receipt
$10B to $20B infrastructure investment required to meet anticipated annual demand of ~30K kg by ~2030
ir_statement / Sep 15, 2026 / receipt
Agilent invested $725M in facility expansion1 to produce up to 1K kg of RNAi per year
ir_statement / Sep 15, 2026 / receipt
Reduces costs and improves purity and yield
ir_statement / Sep 15, 2026 / receipt
Reduces costs and improves purity and yield
ir_statement / Sep 15, 2026 / receipt
Eliminating 46 positions, which is expected to reduce operating expenses by 25%
ir_statement / Sep 15, 2026 / receipt
Reducing operating expenses
ir_statement / Sep 15, 2026 / receipt
Achieving Operational Efficiency
ir_statement / Sep 15, 2026 / receipt
Reduction in expenses across all areas of the organization
ir_statement / Sep 15, 2026 / receipt
| Byron L. Dorgan | director | - | receipt |
| Gordon Sangster | Chief Financial Officer, Senior Vice President | receipt | |
| John Nichols | CEO | - | receipt |
| Stephen Dilley | CEO | - | receipt |
| Stephen Dilly | President and Chief Executive Officer | - | receipt |
| 2026-11-05 | earnings call | scheduled | ir |
| 2022-07-18 | President and Chief Executive Officer, appointed | sec_8k |
| 2014-07-28 | Senior Vice President and Chief Financial Officer, appointed | sec_8k |
| 2014-06-30 | Senior Vice President and Chief Financial Officer, departed | sec_8k |
| 2012-09-04 | Senior Vice President and Chief Financial Officer, appointed | sec_8k |
| 2012-06-21 | Senior Vice President and Chief Business Officer, departed | sec_8k |
| 2012-03-09 | Senior Vice President and Chief Financial Officer, departed | sec_8k |
| 2012-02-21 | director, departed | sec_8k |
| 2011-02-24 | director, appointed | sec_8k |